Brief: Genome & Company Announces Positive Topline Results From Phase 2 Clinical Trial Of Combination Of Gen-001 And Bavencio® For The Treatment Of Gastric Cancer Poster Presented At Asco Gi

Genome&Company

24/01/2024 15:43

Jan 24 (Reuters) - Genome&Company  314130.KQ :
    * GENOME & COMPANY ANNOUNCES POSITIVE TOPLINE RESULTS FROM
PHASE 2
CLINICAL TRIAL OF COMBINATION OF GEN-001 AND BAVENCIO® FOR THE
TREATMENT OF GASTRIC CANCER POSTER PRESENTED AT ASCO GI
    * GENOME&COMPANY: RESULTS SHOWED PARTIAL RESPONSE BEING
CONFIRMED
IN 7 OUT OF 42 PATIENTS
    * GENOME&COMPANY: PARTIAL RESPONSE WAS OBSERVED IN 3 OUT OF
8
PATIENTS WHO WERE PREVIOUSLY TREATED BY IMMUNOTHERAPY

Source text for Eikon:  ID:nPn4YCrQ0a 
Further company coverage:  314130.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))